China is rapidly establishing itself as a major power in health technology, combining mass adoption of AI-driven digital healthcare with a booming pharmaceutical industry that now accounts for roughly half of all global drug licensing deals. The country's vast population of 1.4 billion has accelerated demand for scalable solutions — from WeChat-based hospital bookings to AI doctor avatars — while decades of investment in scientific talent and clinical infrastructure have enabled Chinese biotech firms to develop cancer drugs now being licensed by giants such as Pfizer. Physician and health tech consultant Ruby Wang, whose forthcoming book examines China's rise in this field, warns that proposed U.S. legislation such as the Biosecure Act could restrict access to potentially life-saving medicines, while also noting that technologies proven effective in rural China — affordable ultrasound machines, surgical robots, and scalable diagnostics — hold significant promise for developing nations in Africa and Latin America.